Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...

Johnson & Johnson has achieved a significant milestone in depression treatment as the FDA granted expanded approval for Spravato as a monotherapy for treatment-resistant depression.

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment isn’t ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...